BOSTON SCIENTIFIC CORP (BSX)

Boston Scientific Corporation is a global medical technology company that develops, manufactures, and markets devices used across a broad range of interventional medical specialties, with a mission to transform lives through innovative medical solutions. Operating for more than 40 years, the company advances less-invasive medicine by helping physicians diagnose and treat diseases while providing alternatives to traditional surgery. The company operates through two reportable segments, MedSurg and Cardiovascular, encompassing multiple business units.

Within MedSurg, the Endoscopy business offers hemostatic clips, biliary stents, drainage stent systems, single-use scopes and duodenoscopes, and infection prevention products, and expanded through the 2023 acquisition of Apollo Endosurgery for endoscopic suturing and bariatric devices. The Urology business provides stone management devices, digital ureteroscopes, laser systems, prosthetic urology implants, BPH treatments, and hydrogel systems for prostate cancer radiotherapy, with a pending $3.67 billion acquisition of Axonics announced in January 2024 to add sacral neuromodulation therapies. The Neuromodulation business offers spinal cord stimulation systems, radiofrequency ablation tools, deep brain stimulation systems for Parkinson's disease, and recently acquired Relievant Medsystems for vertebrogenic pain treatment.

Within Cardiovascular, the Interventional Cardiology Therapies business provides intravascular imaging, atherectomy systems, coronary stents, drug-coated balloons, aortic valve systems for TAVR, and cerebral embolic protection devices, along with WATCHMAN left atrial appendage closure devices. The Cardiac Rhythm Management business manufactures implantable defibrillators, pacemakers, cardiac leads, and remote monitoring systems. The Electrophysiology business offers pulsed field ablation and cryoablation systems, mapping systems, and RF ablation catheters for treating heart rhythm disorders.

The Peripheral Interventions business provides stents, balloon catheters, thrombectomy and embolization systems, and interventional oncology products, bolstered by a 2023 majority stake in Acotec Scientific Holdings. The company faces significant competition from major players including Abbott Laboratories and Medtronic, as well as regional competitors, particularly in China, and competes based on clinical and economic outcomes, ease of use, reliability, and price amid a managed care environment. Boston Scientific emphasizes continuous research and development, collaborating with research institutions and clinicians globally to drive innovation, and markets its products in 140 countries through direct sales organizations and distributor networks, while focusing on supply chain efficiency and manufacturing quality to support its growth strategy.

The company also highlights its commitment to corporate social responsibility, including diversity initiatives, environmental protection, and employee well-being programs.